抗白介素2受体α链单抗及AK细胞治疗肝癌的实验研究

Experimental study on the treatment of hepatic carcinoma by anti-interleukin-2 receptor α chain monoclo nal antibody and activated killer cells

目的 探讨一种新的过继免疫治疗肝癌方法。方法 将肝癌细胞株 (H2 2 )接种于近交系BALB/c小鼠皮下 ,制成荷瘤小鼠模型 ,用IL 2 /AK细胞 /抗白介素 2受体α链单抗 (aIL 2RαMAb)治疗 ,以发现其抗肿瘤作用。结果 荷瘤小鼠脾淋巴细胞NK活性无明显变化 ,LAK和CTL活性及淋巴细胞刺激指数在联合治疗组均高于其他各组 (P <0 0 1) ;肝癌皮下结节在联合治疗组明显受到抑制 ,肿瘤小鼠生存期明显延长。结论 IL 2 ,aIL 2RαMAb及AK细胞联合治疗有非常显著的抗肿瘤作用。

Objective This study was to research into a new adoptive immunotherapy against hepatic cancer. Methods Syngeneic BALB/c mice were subcutaneously injected with cells of H22 cell line, which was hepatic cancer cells of murine origin, and a tumor bearing mice model was established. Then the combinative therapy with activated killer cells (AK), IL 2, and an anti IL 2 receptor α chain monoclonal antibody (aIL 2RαMAb) was performed in order to explore its anti tumor role. Results LAK and CTL activities, the lymphocyte transformation rate in the group of combined therapy were all significantly higher than those of controls (P<0 01), but NK activity remained unchanged. Tumor bearing mice in the group of combined therapy showed apparent growth inhibition of subcutaneous tumor and significant prolongation of survival time. Conclusion When IL 2, aIL 2RαMAb and AK cells are used combinatively, the anti tumor effect is evidently intensified.